Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study
Abstract Introduction This retrospective database study explored treatment patterns and potential off-label prescribing among patients newly prescribed fluticasone furoate/vilanterol (FF/VI) in a UK primary care setting. Methods In Europe, FF/VI is approved in two strengths: 100/25 µg for adults wit...
Main Authors: | Daniel Dedman, Sonia J. Coton, Rebecca E. Ghosh, Wilhelmine Meeraus, Courtney Crim, Catherine Harvey, Justyna Amelio, Sarah H. Landis |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-04-01
|
Series: | Pulmonary Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s41030-019-0092-z |
Similar Items
-
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01) -
Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review
by: A. A. Viesel, et al.
Published: (2022-01-01) -
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01) -
Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01) -
Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS
by: Vallejo-Aparicio LA, et al.
Published: (2018-09-01)